Department of Orthopedics, The 960Th Hospital of the PLA Joint Logistice Support Force, No. 25 Shifan Road, Jinan, 250031, China.
BMC Cancer. 2022 Nov 2;22(1):1122. doi: 10.1186/s12885-022-10233-y.
Surgical treatment for recurrent bone tumors in the extremities still presents a challenge. This study was designed to evaluate the clinical value of microwave ablation in the treatment of recurrent bone tumors.
We present 15 patients who underwent microwave ablation for recurrent bone tumors during the last 7 years. The following parameters were analyzed for outcome evaluation: general condition, surgical complications, local disease control, overall survival, and functional score measured using the Musculoskeletal Tumor Society (MSTS) 93 scoring system.
Percutaneous microwave ablation in one patient with osteoid osteoma and another with bone metastasis resulted in postoperative pain relief. Thirteen patients received intraoperative microwave ablation before curettage or resection, including those with giant cell tumors of bone (6), chondroblastoma (2), osteosarcoma (2), undifferentiated sarcoma (1), and bone metastases (2). All patients achieved reasonable local tumor control in the mean follow-up of 29.9 months. The functional score was 24.1 for the 15 patients 6 months after the operation. Four patients had tumor metastasis and died, whereas 3 patients with tumors survived, and the remaining 8 patients without the disease survived.
Microwave ablation represents an optional method for local control in treating recurrent bone tumors in the extremities.
四肢复发性骨肿瘤的外科治疗仍然具有挑战性。本研究旨在评估微波消融在复发性骨肿瘤治疗中的临床价值。
我们回顾性分析了过去 7 年中 15 例行微波消融治疗复发性骨肿瘤的患者。对以下参数进行分析评估：一般情况、手术并发症、局部疾病控制、总生存率和采用肌肉骨骼肿瘤学会（MSTS）93 评分系统测量的功能评分。
1 例骨样骨瘤和 1 例骨转移患者行经皮微波消融后术后疼痛缓解。13 例患者在刮除或切除前接受术中微波消融，包括骨巨细胞瘤 6 例、软骨母细胞瘤 2 例、骨肉瘤 2 例、未分化肉瘤 1 例和骨转移 2 例。所有患者在平均 29.9 个月的随访中均获得了合理的局部肿瘤控制。术后 6 个月，15 例患者的功能评分为 24.1。4 例患者发生肿瘤转移并死亡，3 例肿瘤存活患者和其余 8 例无疾病存活患者。
微波消融是治疗四肢复发性骨肿瘤的一种可选的局部控制方法。
